Bellevue Group AG Buys Shares of 24,166 Masimo Co. (NASDAQ:MASI)

Bellevue Group AG purchased a new stake in Masimo Co. (NASDAQ:MASI - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 24,166 shares of the medical equipment provider's stock, valued at approximately $3,995,000.

Other hedge funds have also modified their holdings of the company. Jones Financial Companies Lllp purchased a new position in Masimo during the fourth quarter worth about $27,000. UMB Bank n.a. boosted its position in shares of Masimo by 180.9% during the 4th quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider's stock worth $32,000 after purchasing an additional 123 shares during the period. Trust Co. of Vermont acquired a new stake in Masimo in the 4th quarter valued at approximately $33,000. Blue Trust Inc. raised its position in Masimo by 56.3% in the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock valued at $33,000 after purchasing an additional 71 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its stake in Masimo by 40.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider's stock worth $37,000 after purchasing an additional 64 shares in the last quarter. 85.96% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Craig B. Reynolds sold 2,053 shares of the stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $166.13, for a total value of $341,064.89. Following the completion of the sale, the director now directly owns 16,581 shares of the company's stock, valued at approximately $2,754,601.53. This represents a 11.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Bilal Muhsin sold 30,000 shares of the company's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the completion of the sale, the chief operating officer now owns 24,172 shares of the company's stock, valued at approximately $4,048,568.28. This trade represents a 55.38 % decrease in their position. The disclosure for this sale can be found here. 9.70% of the stock is owned by corporate insiders.

Masimo Stock Down 0.9 %

Shares of NASDAQ:MASI traded down $1.39 during trading hours on Tuesday, reaching $161.47. The stock had a trading volume of 902,363 shares, compared to its average volume of 662,715. The stock has a market capitalization of $8.73 billion, a price-to-earnings ratio of 111.36 and a beta of 1.23. The firm's 50 day moving average is $164.19 and its 200-day moving average is $166.57. Masimo Co. has a 1 year low of $101.61 and a 1 year high of $194.88. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01.

Masimo (NASDAQ:MASI - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.24 by $0.12. Masimo had a return on equity of 14.98% and a net margin of 3.85%. During the same quarter in the prior year, the business posted $0.77 earnings per share. Masimo's revenue for the quarter was down 24.5% compared to the same quarter last year. Research analysts predict that Masimo Co. will post 4.1 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on MASI. Piper Sandler raised their target price on Masimo from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Needham & Company LLC restated a "hold" rating on shares of Masimo in a report on Thursday, April 10th. Finally, Wells Fargo & Company increased their target price on shares of Masimo from $193.00 to $205.00 and gave the stock an "overweight" rating in a report on Wednesday, February 26th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $194.80.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.